ChemoCentryx (NASDAQ:CCXI) Releases Quarterly Earnings Results

ChemoCentryx (NASDAQ:CCXIGet Rating) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.24), MarketWatch Earnings reports. ChemoCentryx had a negative net margin of 408.87% and a negative return on equity of 40.75%. During the same period last year, the company posted ($0.43) earnings per share.

Shares of NASDAQ:CCXI traded up $1.74 during midday trading on Friday, reaching $17.38. The company had a trading volume of 8,372,826 shares, compared to its average volume of 1,178,439. The company has a quick ratio of 4.26, a current ratio of 4.27 and a debt-to-equity ratio of 0.02. The business’s 50 day moving average price is $22.63 and its 200 day moving average price is $29.94. The stock has a market cap of $1.21 billion, a PE ratio of -8.65 and a beta of 1.96. ChemoCentryx has a 1-year low of $9.53 and a 1-year high of $42.16.

Several analysts have issued reports on the company. Stifel Nicolaus reissued a “buy” rating and issued a $85.00 price target on shares of ChemoCentryx in a research note on Friday, March 18th. began coverage on ChemoCentryx in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $73.43.

Several large investors have recently added to or reduced their stakes in CCXI. Neo Ivy Capital Management acquired a new stake in shares of ChemoCentryx in the fourth quarter valued at about $86,000. Royal Bank of Canada grew its holdings in ChemoCentryx by 288.1% during the second quarter. Royal Bank of Canada now owns 8,794 shares of the biopharmaceutical company’s stock worth $118,000 after purchasing an additional 6,528 shares during the period. Amalgamated Bank bought a new position in ChemoCentryx during the fourth quarter worth about $262,000. Schonfeld Strategic Advisors LLC grew its holdings in ChemoCentryx by 110.0% during the fourth quarter. Schonfeld Strategic Advisors LLC now owns 7,500 shares of the biopharmaceutical company’s stock worth $273,000 after purchasing an additional 82,500 shares during the period. Finally, OLD Mission Capital LLC bought a new position in ChemoCentryx during the third quarter worth about $423,000. 82.28% of the stock is currently owned by institutional investors and hedge funds.

ChemoCentryx Company Profile (Get Rating)

ChemoCentryx, Inc, a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis.

Recommended Stories

Earnings History for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with's FREE daily email newsletter.